|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The final purpose is to better clarify which can be the role of MET as a therapeutic target in HCC.
|
24045150 |
2014 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.
|
28714063 |
2017 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Heat-stress induced MET and EGFR signalling is distinct from growth factor mediated signalling in HCC cells and MET inhibition enhances heat stress induced HCC cell killing via a PI3K/AKT/mTOR-independent mechanism.
|
28954551 |
2018 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Twenty-two percent of advanced HCC harbored potentially druggable genetic alterations, and MET amplification was associated with complete tumor response in patients with advanced HCC treated by a specific MET inhibitor.
|
31206197 |
2020 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
LHGDN |
Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
|
19065669 |
2009 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Treatment of primary cancer cells from patients with HCC expressing both phospho-FGFR and phospho-MET with PHA665752 did not induce cell death, whereas AZD4547 treatment induced cell death through the cleavage of caspase-3.
|
26351320 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.
|
11381087 |
2001 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The expression in HA was variable and differed between molecular subtypes of this neoplasm: inflammatory and HNF1A mutation-associated type are characterized by overexpression of c-MET to an extent comparable with poorly-differentiated HCC, whereas Wnt/β-catenin dysfunction-associated type lacks overexpression, and the amount of c-MET protein accumulated in its cells is similar to the levels in non-neoplastic tissue and well- to moderately-differentiated HCC.
|
29256857 |
2017 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
HCC samples from patients had lower levels of miR-449 and higher levels of c-MET than human reference.
|
22641068 |
2012 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Taken together, it can be anticipated that more effective and safer c-Met targeting strategies for preventing HCC progression can be established in the future.
|
28587113 |
2017 |
|
Liver carcinoma
|
1.000 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Therefore, it is crucial to investigate the expression of C-MET and PD-L1, and their association with clinicopathologic factors, to facilitate the development of targeted treatments for HCC.
|
31186768 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
These encode genes, such as EGFR and MET, previously associated with HCC and others, such as UBE2H, that are potential new targets for treating this neoplasm.
|
19234449 |
2009 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
LHGDN |
Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
|
16331686 |
2006 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Amphotropic retroviruses with modified envelope displaying single-chain antibody fragment (scFv) directed against the c-Met receptor were recently generated and found to efficiently and selectively deliver genes into hepatocarcinoma cells.
|
16082194 |
2005 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tivantinib has been described as a highly selective inhibitor of MET and is currently in a phase III clinical trial for the treatment of hepatocellular carcinoma (HCC).
|
26458953 |
2015 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of c-Met protein has been detected in hepatocellular carcinoma (HCC).
|
29163834 |
2017 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We assessed nine single nucleotide polymorphisms (SNPs) in the FGF1, FGF2, FGF receptor (FGFR)-2, Flt-1, and c-MET genes in 245 HCC patients and 483 chronic hepatitis B virus (HBV) carriers without HCC.
|
30952770 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
On the contrary, another lead is to study target a specific TKI such as c-MET inhibitors or TGFβR inhibitors in HCC sub-populations with promising results in early phase trials.
|
28604110 |
2017 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
UNIPROT |
Our results indicate that mutations of the tyrosine kinase domain of the MET gene may be involved in the acceleration of the carcinogenesis in childhood HCC.
|
9927037 |
1999 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
However, in our recently published studies, we have documented that AAV3 vectors transduce human liver cancer - hepatoblastoma (HB) and hepatocellular carcinoma (HCC) - cell lines extremely efficiently because AAV3 utilizes human hepatocyte growth factor receptor as a cellular co-receptor for binding and entry in these cells.
|
21445055 |
2011 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis was used to measure the expression of hepatocyte growth factor receptor (c-Met), β-catenin and focal adhesion kinase (FAK) in patients with HCC. c-Met expression was identified to be high in patients with larger tumors, higher α-fetoprotein (AFP) levels, higher Edmondson grades, portal vein invasion and higher tumor-node-metastasis (TNM) stages.
|
29467897 |
2018 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
AMG 337 significantly inhibited tumor growth at all doses tested in the MET-amplified and MET-high-expressing hepatocellular carcinoma PDX model LI0612 and had no effect on tumor growth in the non-MET-amplified and MET-low-expressing hepatocellular carcinoma PDX model LI1078.
|
27196749 |
2016 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the ability of a retroviral amphotropic envelope displaying single-chain variable-fragment (scFv) directed against the c-Met receptor, to target the entry of recombinant retroviruses to human hepatocarcinoma cells.
|
14605670 |
2003 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels.
|
25633810 |
2015 |